real-time news and commentary for investors
Wednesday, Sep 4
Merck's Durham N.C. site gets FDA approval to manufacture bulk varicella
- Merck (MRK) says its Durham site has received FDA clearance to manufacture bulk varicella at its site in Durham, North Carolina.
- The approval enables the site to produce bulk varicella which is used in MRK's vaccines to protect against chickenpox and shingles.
- In 2010, the site was approved to produce finished chickenpox vaccines.
- Over the longer term, the company plans for the site to produce bulk and finished product for other Merck childhood vaccines, and for the shingles vaccines as well.